dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus by Garcia-Soria, G, Gonzalez-Galvez, G, Argoud, G.M, Gerstman, M, Littlejohn, T.W. III, Schwartz, S.L, O'Farrell, A.-M, Li, X, Cherrington, J.M, Bennett, C, Guler, H.-P

Get full text

Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses by Mulato, A.S, Cherrington, J.M

Get full text

NF‐kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation by Sambucetti, L.C., Cherrington, J.M., Wilkinson, G.W., Mocarski, E.S.

Get full text

Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy by Bowen, E.F., Cherrington, J.M., Lamy, P.D., Griffiths, P.D., Johnson, M.A., Emery, V.C.

Get full text

Synthesis and antiviral activity of novel phosphonomethyl ether nucleosides by Bischofberger, N., Kern, E.R., Chen, M.S., Barkhimer, D.B., Cherrington, J.M., Dougherty, J.P., Kim, C.U., Lew, W., Mendel, D.B., Moon, K., Mulato, A.S., Williams, M.A., Yang, W.

Get full text

Tissue distribution and induction of the rat multidrug resistance-associated proteins 5 and 6 by Maher, J.M., Cherrington, N.J., Slitt, A.L., Klaassen, C.D.

Get full text

Susceptibility of Human Cytomegalovirus to Cidofovir Is Unchanged after Limited In Vivo Exposure to Various Clinical Regimens of Drug by Cherrington, J. M., Miner, R., Hitchcock, M. J. M., Lalezari, J. P., Drew, W. L.

Get full text